The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review

References

• Paller AS, Siegfried EC, Vekeman F, et al. Treatment patterns of pediatric patients with atopic dermatitis: a claims data analysis. J Am Acad Dermatol. 2020;82(3):1–8. doi: 10.1016/j.jaad.2019.07.105.
   PubMed Web of Science ®Google Scholar
• Abuabara K, Magyari A, McCulloch CE, et al. Prevalence of atopic eczema among patients seen in primary care: data from the health improvement network. Ann Intern Med. 2019;170(5):354–356. doi: 10.7326/M18-2246.
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review [review. Dermatol Ther. 2017;7(1):1–23. doi: 10.1007/s13555-016-0170-1.
   PubMed Web of Science ®Google Scholar
• Johansson EK, Brenneche A, Trangbaek D, et al. Treatment patterns among patients with atopic dermatitis in secondary care: a national, observational, non-interventional, retrospective study in Sweden. Acta Derm Venereol. 2022;102:adv00774. doi: 10.2340/actadv.v102.1986.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. doi: 10.1111/jdv.14888.
   Google Scholar
• Arents BWM, Breukels MA, Bruijnzeel-Koomen C, et al. Constitutioneel eczeem - Richtlijn 2019. Nederlandse Vereniging Voor Dermatologie En Venereologie (NVDV) website. 2019. Available from: https://nvdv.nl/professionals/richtlijnen-en-onderzoek/richtlijnen/richtlijn-constitutioneel-eczeem (Accessed: 12 September 2023).
   Google Scholar
• Damiani G, Calzavara-Pinton P, Stingeni L, et al. Italian guidelines for therapy of atopic dermatitis-adapted from consensus-based european guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther. 2019;32(6):e13121. doi: 10.1111/dth.13121.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi: 10.1111/jdv.16892.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30(5):729–747. doi: 10.1111/jdv.13599.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based european guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II [letter. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. doi: 10.1111/jdv.14888.
   PubMed Web of Science ®Google Scholar
• Lyakhovitsky A, Barzilai A, Heyman R, et al. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol. 2010;24(1):43–49. doi: 10.1111/j.1468-3083.2009.03351.x.
   PubMed Web of Science ®Google Scholar
• Purvis D, Lee M, Agnew K, et al. Long-term effect of methotrexate for childhood atopic dermatitis. J Paediatr Child Health. 2019;55(12):1487–1491. doi: 10.1111/jpc.14478.
   PubMed Web of Science ®Google Scholar
• Weatherhead SC, Wahie S, Reynolds NJ, et al. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007;156(2):346–351. doi: 10.1111/j.1365-2133.2006.07686.x.
   PubMed Web of Science ®Google Scholar
• Chen KS, Tan TH, Yesu PD. Clinical, demographic and laboratory characteristics of methotrexate‐responsive eczema. J Eur Acad Dermatol Venerol. 2015;11:158–159.
   Google Scholar
• Gerbens LAA, Hamann SAS, Brouwer MWD, et al. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial [comparative study, pragmatic clinical trial, randomized controlled trial]. Br J Dermatol. 2018;178(6):1288–1296. doi: 10.1111/bjd.16240.
   PubMed Web of Science ®Google Scholar
• Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema [randomized controlled trial]. J Allergy Clin Immunol. 2011;128(2):353–359. doi: 10.1016/j.jaci.2011.03.024.
   PubMed Web of Science ®Google Scholar
• Shah N, Alhusayen R, Walsh S, et al. Methotrexate in the treatment of moderate to severe atopic dermatitis: a retrospective study. J Cutan Med Surg. 2018;22(5):484–487. doi: 10.1177/1203475418781336.
   PubMed Web of Science ®Google Scholar
• Roekevisch E, Schram ME, Leeflang MMG, et al. Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data [comparative study letter. J Allergy Clin Immunol. 2018;141(2):825.e10–827.e10. doi: 10.1016/j.jaci.2017.09.033.
   Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents [practice guideline, research support, N.I.H., extramural]. J Am Acad Dermatol. 2014;71(2):327–349. doi: 10.1016/j.jaad.2014.03.030.
   PubMed Web of Science ®Google Scholar
• Shah RA, Nwannunu CE, Limmer AL, et al. Brief update on dermatologic uses of methotrexate [review]. Skin Therapy Lett. 2019;24(6):5–8.
   Google Scholar
• Malaviya AN. Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story. Int J Rheum Dis. 2016;19(9):844–851. doi: 10.1111/1756-185X.12862.
   PubMed Web of Science ®Google Scholar
• Methotrexate 2.5 mg and 10 mg Tablets SmPC. 2023. Available from: https://www.geneesmiddeleninformatiebank.nl/smpc/h09957_smpc.pdf (Accessed: 12 September 2023).
   Google Scholar
• Bulur I, Erdoğan HK, Karapınar T, et al. Morphea in middle anatolia, Turkey: a 5-year single-center experience. Postepy Dermatol Alergol. 2017;34(4):334–338. doi: 10.5114/ada.2017.69313.
   PubMed Web of Science ®Google Scholar
• Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008;144(5):612–616. doi: 10.1001/archderm.144.5.612.
   PubMedGoogle Scholar
• Lim SL, Kwon IS, Im M, et al. Low-dose systemic methotrexate therapy for recalcitrant alopecia areata. Ann Dermatol. 2017;29(3):263–267. doi: 10.5021/ad.2017.29.3.263.
   PubMed Web of Science ®Google Scholar
• Eckert L, Amand C, Gadkari A, et al. Treatment patterns in UK adult patients with atopic dermatitis treated with systemic immunosuppressants: data from the health improvement network (THIN). J Dermatol Treat. 2019;31(8):815–820. doi: 10.1080/09546634.2019.1639604.
   PubMed Web of Science ®Google Scholar
• Garritsen FM, van den Heuvel JM, Bruijnzeel-Koomen C, et al. Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands. J Eur Acad Dermatol Venereol. 2018;32(8):1336–1342. doi: 10.1111/jdv.14896.
   PubMed Web of Science ®Google Scholar
• Taylor K, Swan DJ, Affleck A, et al. Treatment of moderate-to-­severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol. 2017;176(6):1617–1623. doi: 10.1111/bjd.15235.
   PubMed Web of Science ®Google Scholar
• El-Khalawany MA, Hassan H, Shaaban D, et al. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt [comparative study, multicenter study, randomized controlled ­trial]. Eur J Pediatr. 2013;172(3):351–356. doi: 10.1007/s00431-012-1893-3.
   PubMed Web of Science ®Google Scholar
• Goujon C, Viguier M, Staumont-Salle D, et al. Methotrexate Versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial [clinical trial, phase III, multicenter study, randomized controlled trial, research support, non-U.S]. J Allergy Clin Immunol Pract. 2018;6(2):562.e3–569.e3. doi: 10.1016/j.jaip.2017.07.007.
   Web of Science ®Google Scholar
• Law Ping Man S, Bouzille G, Beneton N, et al. Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine [comparative study]. J Eur Acad Dermatol Venereol. 2018;32(8):1327–1335. doi: 10.1111/jdv.14880.
   PubMed Web of Science ®Google Scholar
• Prezzano JC, Beck LA. Long-term treatment of atopic dermatitis. Dermatol Clin. 2017;35(3):335–349. doi: 10.1016/j.det.2017.02.007.
   PubMed Web of Science ®Google Scholar
• Shen S, O’Brien T, Yap LM, et al. The use of methotrexate in dermatology: a review. Australas J Dermatol. 2012;53(1):1–18. doi: 10.1111/j.1440-0960.2011.00839.x.
   PubMed Web of Science ®Google Scholar
• Schnabel A, Reinhold-Keller E, Willmann V, et al. Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. Rheumatol Int. 1994;14(1):33–38. doi: 10.1007/BF00302669.
   PubMed Web of Science ®Google Scholar
• Verstappen SMM, Jacobs JWG, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66(11):1443–1449. doi: 10.1136/ard.2007.071092.
   PubMed Web of Science ®Google Scholar
• Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094–1099. doi: 10.1136/ard.2008.092668.
   PubMed Web of Science ®Google Scholar
• Menting SP, Dekker PM, Limpens J, et al. Methotrexate dosing regimen for plaque-type psoriasis: a systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation. Acta Derm Venereol. 2016;96(1):23–28. doi: 10.2340/00015555-2081.
   PubMed Web of Science ®Google Scholar
• van Huizen AM, Menting SP, Gyulai R, et al. International eDelphi study to reach consensus on the methotrexate dosing regimen in patients With psoriasis. JAMA Dermatol. 2022;158(5):561–572. doi: 10.1001/jamadermatol.2022.0434.
   PubMed Web of Science ®Google Scholar
• van Huizen AM, Sikkel R, Caron AGM, et al. Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review. J Dermatolog Treat. 2022;33(8):3104–3118. doi: 10.1080/09546634.2022.2117539.
   PubMed Web of Science ®Google Scholar
• Damiani G, Amerio P, Bardazzi F, et al. Real-world experience of methotrexate in the treatment of skin diseases: an Italian Delphi consensus. Dermatol Ther. 2023;13(6):1219–1241. doi: 10.1007/s13555-023-00930-2.
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. doi: 10.1186/s13643-021-01626-4.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Aoki V, Lorenzini D, Orfali RL, et al. Consensus on the therapeutic management of atopic dermatitis - Brazilian society of dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):67–75. doi: 10.1590/abd1806-4841.2019940210.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Belloni Fortina A, Galli E, et al. Current therapeutic paradigm in pediatric atopic dermatitis: practical guidance from a national expert panel [review]. Allergol Immunopathol. 2019;47(2):194–206. doi: 10.1016/j.aller.2018.06.008.
   PubMed Web of Science ®Google Scholar
• Chow S, Seow CS, Dizon MV, et al. A clinician’s reference guide for the management of atopic dermatitis in asians. Asia Pac Allergy. 2018;8(4):e41. doi: 10.5415/apallergy.2018.8.e41.
   PubMedGoogle Scholar
• Ertam İ, Su Ö, Alper S, et al. The turkish guideline for the diagnosis and management of atopic dermatitis-2018. Turkdem - Turk Arch Dermatol Venereol. 2018;52(1):6–23. doi: 10.4274/turkderm.87143.
   Google Scholar
• Kulthanan K, Tuchinda P, Nitiyarom R, et al. Clinical practice guidelines for the diagnosis and management of atopic dermatitis. Asian Pac J Allergy Immunol. 2021;39(3):145–155.
   PubMed Web of Science ®Google Scholar
• Lansang P, Lam JM, Marcoux D, et al. Approach to the assessment and management of pediatric patients With atopic dermatitis: a consensus document. Section III: treatment options for pediatric atopic dermatitis. J Cutan Med Surg. 2019;23(5_suppl):19S–31S. doi: 10.1177/1203475419882647.
   PubMed Web of Science ®Google Scholar
• Nowicki RJ, Trzeciak M, Kaczmarski M, et al. Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part II. Systemic treatment and new therapeutic methods. Postepy Dermatol Alergol. 2020;37(2):129–134. doi: 10.5114/ada.2020.94829.
   PubMed Web of Science ®Google Scholar
• Parikh D, Dhar S, Ramamoorthy R, et al. Treatment guidelines for atopic dermatitis by ISPD task force 2016. Indian J Paediatr Dermatol. 2018;19(2):108–115. doi: 10.4103/ijpd.IJPD_28_18.
   Google Scholar
• Popadic S, Gajic-Veljic M, Prcic S, et al. National guidelines for the treatment of atopic dermatitis [review]. Serbian J Dermatol Venereol. 2016;8(3):129–153.
   Google Scholar
• Rubel D, Thirumoorthy T, Soebaryo RW, et al. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. J Dermatol. 2013;40(3):160–171. doi: 10.1111/1346-8138.12065.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Kodama S. Atopic dermatitis guidelines: diagnosis, systemic therapy, and adjunctive care. Clin Dermatol. 2018;36(5):648–652. doi: 10.1016/j.clindermatol.2018.05.008.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the international eczema council [consensus development conference, systematic review]. J Am Acad Dermatol. 2017;77(4):623–633. doi: 10.1016/j.jaad.2017.06.042.
   PubMed Web of Science ®Google Scholar
• Deleuran M, Fage S, Bang K, et al. Investigation and treatment of patients with atopic dermatitis (AD) (in Danish). Danish Dermatological Society website. 2020. Available from: https://dds.nu/wp-content/uploads/2020/11/AD-guideline-oktober-2020.pdf (Accessed: 12 September 2023).
   Google Scholar
• Tiplica G, Salavastru CM, Szepietowski J, et al. Recommended strategies for atopic dermatitis management in Romania. Ro Med J. 2019;66(4):335–341. doi: 10.37897/RMJ.2019.4.8.
   Google Scholar
• Schmitt J, Spuls PI, Thomas KS, et al. The harmonising outcome measures for eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4):800–807. doi: 10.1016/j.jaci.2014.07.043.
   PubMed Web of Science ®Google Scholar
• Williams HC, Schmitt J, Thomas KS, et al. The HOME core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol. 2022;149(6):1899–1911. doi: 10.1016/j.jaci.2022.03.017.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Arkin LM, Chiu YE, et al. Methotrexate for inflammatory skin disease in pediatric patients: consensus treatment guidelines. Pediatr Dermatol. 2023;40(5):789–808. doi: 10.1111/pde.15327.
   PubMedGoogle Scholar
• Yao TC, Wang IJ, Sun HL, et al. Taiwan guidelines for the diagnosis and management of pediatric atopic dermatitis: consensus statement of the Taiwan academy of pediatric allergy, asthma and immunology. J Microbiol Immunol Infect. 2022;55(4):561–572. doi: 10.1016/j.jmii.2022.03.004.
   PubMedGoogle Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: 10.1111/jdv.18345.
   PubMed Web of Science ®Google Scholar
• Grissinger M. Severe harm and death associated with errors and drug interactions involving low-dose methotrexate. Pharm Ther. 2018;43(4):191–248.
   Google Scholar
• Vesseur J, Feenstra J. Methotrexaat; fatale doseringsfouten door onoplettendheid. Ned Tijdschr Geneeskd. 1996;140(30):1533–1535.
   PubMedGoogle Scholar
• European Medical Agency (EMA). PRAC recommends new measures to avoid dosing errors with methotrexate. EMA website. 2019. Available from: https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-prac-recommends-new-measures-avoid-dosing-errors-methotrexate_en.pdf (Accessed: 12 September 2023).
   Google Scholar
• Czarnowicki T, Malajian D, Shemer A, et al. Skin-homing and systemic T-cell subsets show higher activation in atopic ­dermatitis versus psoriasis. J Allergy Clin Immunol. 2015;136(1):208–211. doi: 10.1016/j.jaci.2015.03.032.
   PubMed Web of Science ®Google Scholar
• Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102(2):322–328. doi: 10.1172/JCI2676.
   PubMed Web of Science ®Google Scholar
• Goujon C, Nicolas JF, Nosbaum A. Methotrexate in atopic ­eczema. Comments to: consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2019;33(4):e154–e155. doi: 10.1111/jdv.15386.
   PubMed Web of Science ®Google Scholar